Avidity Biosciences could be about to transform treatment of three muscular dystrophy diseases with first-in-class RNA-based therapies, the most advanced being on track for filing by the end of 2025.
Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025
The company is moving quickly to bring its antibody oligonucleotide conjugates to patients in three separate muscular dystrophy diseases, causing unease for its rivals.
